期刊文献+

三氟甲基烷基酮的生物活性及合成方法 被引量:1

Bioactivities and Synthesis of Trifluoromethyl Alkyl Ketones
原文传递
导出
摘要 三氟甲基烷基酮类化合物(TFMKs)具有独特的生理活性,三氟甲基能够增强化合物的亲脂性、代谢稳定性以及生物利用度。由于三氟乙酰基强烈的吸电子特性,TFMKs能够与目标水解酶形成稳定的半缩酮加合物,对生命体内多种活性酶起到抑制作用。最新的两个重要发现是TFMKs可以抑制SARS病毒和应用于眼科疾病,含氟原子数目、部位、有机碳链长度、不饱和度、其他官能团种类都是影响TFMKs作用的因素。TFMKs类化合物的合成方法,包括烃基金属试剂与三氟乙酸衍生物反应、使用三氟甲基化试剂TMS-CF3与羰基衍生物反应、三氟甲基仲醇氧化、羧酸与三氟乙酸酐/吡啶反应等方法。本文按照其作用的途径进行分类,归纳了三氟甲基烷基酮类化合物的药理活性,对现有的三氟甲基烷基酮类化合物合成方法进行了总结。 With high lipophicity and metabolic stability, trifluoromethyl alkyl ketones (TFMKs) act as important bioactive molecules, especially enzyme inhibitors. Besides, they are superior intermediates for pharmaceuticals and materials. Due to severe electrophilicity of trifluoromethyl, TFMKs form covalent hemiketal adducts targeting at many hydrolytic enzymes such as phospholipase A2 (PLA2) both in mammal and plant, human leukocyte elastase, oleamide hydrolase, human plasma kallikrein, pig liver esterase. TFMKs are inhibitors of human renin in the regulation of blood pressure and electrolyte homeostasis. Structure of chymotrypsin-trifluoromethyl ketone inhibitor complexes have been presented by XRD and NMR spectroscopy, this inhibition is depended on pH. TFMKs are also served as outstanding inhibitors of SARS-CoV 3CL protease. Diversity methods have been used in synthesis of TFMKs, involving the reactions of organometallic reagent like Grignard reagent or alkyl lithium with trifluoromethyl acid, acetate, or their salts, ester or amide react with TMSCF3 or Et3GeNa/PhSCF3 to generate nucleophilic trifluoromethylation, treatment of carboxylic acid chlorides with pyridine and trifluoroacetic anhydride, sulfone-mediated synthesis of TFMKs from alkyl and alkenyl bromides, oxidation of trifluoromethyl carbinols, catalytic aerobic oxidative decarboxylation of trifluoromethylhydroxy acids, conversion of trifluoroethyl amines by the treatment of NBS/DBU, conversion ofenolizable carboxylic acids to TFMKs via enediolate trifluoroacetylation/decarboxylation, and ring opening ot alkyl 2-siloxycyclopropanecarboxylates by triethylamine trihydrofluoride. Bioactive TFMKs on enzyme inhibition are summarized and synthesis methods are discussed described. in this paper, trend on both application and preparation are
出处 《化学进展》 SCIE CAS CSCD 北大核心 2014年第6期976-986,共11页 Progress in Chemistry
基金 国家自然科学基金项目(No.21376040) 教育部留学回国人员科研启动基金项目(No.20121707) 中央高校基本科研业务费专项资金项目(No.DUT13LAB03)资助~~
关键词 三氟甲基烷基酮 生物活性 酶抑制剂 合成 trifluoromethyl alkyl ketones bioactivities enzyme inhibitor synthesis
  • 相关文献

参考文献98

  • 1Muller K, Faeh C, Diederich F. Science, 2007, 317: 1881.
  • 2Furuya T, Kamlet A S, Ritter T. Nature, 2011, 473 : 470.
  • 3Ismail F M D. J. Fluorine Chem. , 2002, 118 (1-2) : 27.
  • 4Purser S, Moore P R, Swallow S, Gouverneur V. Chem. Soc. Rev. , 2008, 37 (2) : 320.
  • 5Pierce M E, Parsons R L, Jr, Radesca L A, Lo Y S, Silverman S, Moore J R, Islam Q, Choadhury A, Fortunak J M D, Nguyen D, Luo C, Morgan S J, Davis W P, Confalone P N. J. Org. Chem. , 1998, 63 (23) : 8536.
  • 6刘金涛.中国有机氟化学研究40年[J].化学通报,2001,64(1):60-62. 被引量:9
  • 7Wang Y S, FangX Q, Chen H Y, Wu B, WangZ Y U. Hilty C, Liu W R. ACS Chem. Biol. , 2013, 8: 405.
  • 8Zhang H, Li Y, Jiang Z X. J. Biomol. Res. Ther. 2012, 1 : e107.
  • 9Olvera L I, Guzman-GutiSrrez M T, Zolotukhin M G, Fomlne S, Catrdenas J, Ruiz-Trevino F A, Villers D, Ezquerra T A, Prokhorov E. Macromolecules, 2013, 46: 7245.
  • 10Kiss L E, Ferreira H S, Learmonth D A. Org. Lett. , 2008, 10: 1835.

二级参考文献98

  • 1黄维垣,中国有机氟化学十年进展,1999年
  • 2黄维垣,中国有机氟化学研究,1996年
  • 3Furuya T, Kamlet A S, Ritter T. Nature, 2011, 473: 470-477.
  • 4Muller K, Faeh C, Diederich F. Science, 2007, 317: 1881-1886.
  • 5Meanwell N A J. Med. Chem., 2011, 54: 2529-2591.
  • 6Kirsch P. Modern Fluoroorganic Chemistry, Weinheim: Wiley-VCH, Germany, 2004, 203-278.
  • 7Lundgren R J, Stradiotto M. Angew. Chem. Int. Ed., 2010, 49: 9322-9324.
  • 8Tomashenko O A, Grushin V V. Chem. Rev., 2011, 111: 4475-4521.
  • 9Roy S, Gregg B T, Gribble G W, Le V D. Tetrahedron, 2011, 67: 2161-2195.
  • 10Zhang C P, Wang Z L, Chen Q Y, Zhang C T, Gu Y C, Xiao J C. Angew. Chem. Int. Ed., 2011, 50: 1896-1900.

共引文献19

同被引文献20

  • 1程隆新.含三氟甲基农药的开发进展[J].现代农药,2004,3(3):7-11. 被引量:11
  • 2WU Yong-ming,DENG Juan,XIANG Fang’et al. Regios-elective synthesis of fluoroalkylated [ I ,2,3] -triazoles byHuisgen cycloaddition[ J] . Chem. Lett. ,2004,10(125);1415-1 423.
  • 3DUBED,BRIDEAU C. 2-Heterosubstituted-3-(4-methyl-sulfonyl) phenyl-5 -trifluoromethyl pyridines as selectiveand orally active cyclooxygenase-2 inhibitors [ J ]. Bioorg.Med. Chem. Lett. ,1999,9(12) :1 715-1 720.
  • 4ZHANG Han-zhong, KASIBHATLA S. Discovery andstructure-activity relationship of 3-aryl-5-aryl-1, 2, 4-ox-adiazoles as a new series of apoptosis inducers and poten-tial anticancer agents[ J] . ?7‘ Med. Chem. ,2005 ,48( 16):5 215-5 223.
  • 5DOHERTY M E,F0TSCH Y C,BO Yun-xin,et al. Dis-covery of potent,orally available vanilloid receptor-1 an-tagonists. structure-activity relationship of N-ary\ cin-namides[J]. J. Med. Chem. ,2005 ,48(1) :71-90.
  • 6张小兵.啶氧菌酯的制备方法:中国专利,103626 691[P].2013-11-11.
  • 7COUYREVE, MLLEES. Preparation of 1,2,4-triazin-3-amine derivatives as Al and A2a receptor inhibitorsuseful in the treatment of diseases:PCT,2 011 095 625[P]. 2011-02-07.
  • 8CONLEA, KUEHNE H. Preparation of iV-benzylbenzamides,pyridinecarboxamides and pyrimidinecar-boxamides as cholesteryl ester transfer protein ( CETP). inhibitors for the treatment of dyslipidemia : American,20 070 185 058[P].2007-08-09.
  • 9HU Jing-dan. 1 , 5-Diphenylpyrrolidin-2-one derivativesas GB-1 ligands and their preparation, pharmace-uticalcompositions and use in the treatment of diseases :PCT,2009 131 814[P].2009-10-29.
  • 10FINLY H. Triazolo and imidazo dihydropyrazolopyrimi-dine potassium channel antagonists [ J ]. Bioorg. Med.Chem. Lett. ,2013,23(6) ; 1743-1747.

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部